Skip to main navigation Skip to search Skip to main content

Nephrotoxicity of concomitant piperacillin/tazobactam and teicoplanin compared with monotherapy

  • JD Workum
  • , C Kramers
  • , E Kolwijck
  • , JA Schouten
  • , Saskia de Wildt
  • , RJM Brüggemann

Research output: Contribution to journalArticleAcademicpeer-review

13 Citations (Scopus)

Abstract

Objectives: Piperacillin/tazobactam combined with vancomycin has been associated with a decline in renal function when compared with monotherapy. Teicoplanin is a glycopeptide similar to vancomycin. We investigated whether piperacillin/tazobactam combined with teicoplanin is associated with a decline in renal function aswell. Methods: We conducted a single-centre retrospective cohort study with data from our electronic health records from 9 August 2013 to 15 November 2019, including all adult patients that received either piperacillin/tazobactam, teicoplanin or piperacillin/tazobactam ! teicoplanin. The incidence of acute kidney injury (AKI) at 48-72 h served as the primary outcome, whereas change in serumcreatinine served as a secondary outcome. Results: Of the 4202 included patients, 3188 (75.9%) received piperacillin/tazobactam, 791 (18.8%) received teicoplanin and 223 (5.3%) received piperacillin/tazobactam ! teicoplanin. The incidence of AKI at 48-72 h after commencement of antibiotic therapy was 5.4% for piperacillin/tazobactam, 3.4% for teicoplanin and 11.7% for piperacillin/tazobactam ! teicoplanin (P < 0.001). However, mean serum creatinine at 48-72 h was slightly higher in the piperacillin/tazobactam ! teicoplanin group therapy compared with baseline [!1.61% (95% CI -2.25 to 5.70)], indicating a slight decrease in renal function, and decreased for piperacillin/tazobactam [-1.98% (95% CI -2.73 to -1.22)] and teicoplanin [-8.01% (95% CI -9.54 to -6.45)]. After correcting for significant confounders in a multivariate linear regression analysis, these patterns remained. Conclusions: Our study suggests that piperacillin/tazobactam ! teicoplanin is associated with a higher prevalence of AKI compared with monotherapy. However, as the overall decline in renal function with piperacillin/ tazobactam ! teicoplanin is very small, its clinical relevance is likely limited. Therefore, piperacillin/tazobactam ! teicoplanin can probably be safely combined.

Original languageEnglish
Pages (from-to)212-219
Number of pages8
JournalThe Journal of antimicrobial chemotherapy
Volume76
Issue number1
DOIs
Publication statusPublished - Jan 2021

Bibliographical note

Funding Information:
S.N. de W. reports grants from the European Union (H2020, IMI2), grants from Bill and Melinda Gates Foundation and grants from Health Holland, outside the submitted work. The foundations have no role in the design, implementation, interpretation or reporting of the study. The other authors have no conflicts of interest relevant to this article to declare.

Publisher Copyright:
© The Author(s) 2020.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Research programs

  • EMC OR-01

Fingerprint

Dive into the research topics of 'Nephrotoxicity of concomitant piperacillin/tazobactam and teicoplanin compared with monotherapy'. Together they form a unique fingerprint.

Cite this